WEDNESDAY, July 31 (HealthDay News) -- A higher dose of atorvastatin is more effective than a lower dose in reducing biomarkers of inflammation and oxidative stress in patients with metabolic syndrome, according to a study in the Aug. 1 issue of the Journal of the American College of Cardiology.
Uma Singh, Ph.D., and colleagues from the University of California Davis Medical Center in Sacramento randomly assigned 70 subjects with metabolic syndrome to placebo or 10 or 80 milligrams per day atorvastatin for 12 weeks.
The researchers found that 80 milligrams atorvastatin was more effective than 10 milligrams in reducing total, low-density lipoprotein (LDL), non-high-density lipoprotein and oxidized LDL cholesterol. The 80-milligram group also had significant reductions in high-sensitivity C-reactive protein (hs-CRP), matrix metalloproteinase-9 and nuclear factor kappa-B (NF-kB) activity compared with baseline.
"In conclusion, this randomized trial of subjects with metabolic syndrome showed the superiority of atorvastatin 80 mg compared with its 10-mg dose in decreasing oxidized LDL, hs-CRP, matrix metalloproteinase-9, and NF-kB activity," Singh and colleagues write.
Abstract
Full Text (subscription or payment may be required)
